These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

631 related items for PubMed ID: 27014750

  • 1. Effects of Smoking on Pegylated Interferon alpha 2a and First Generation Protease Inhibitor-based Antiviral Therapy in Naïve Patients Infected with Hepatitis C Virus Genotype 1.
    Zimmermann T, Hueppe D, Mauss S, Buggisch P, Pfeiffer-Vornkahl H, Grimm D, Galle PR, Alshuth U.
    J Gastrointestin Liver Dis; 2016 Mar; 25(1):15-24. PubMed ID: 27014750
    [Abstract] [Full Text] [Related]

  • 2. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
    Ferenci P, Reddy KR.
    Antivir Ther; 2011 Mar; 16(8):1187-201. PubMed ID: 22155901
    [Abstract] [Full Text] [Related]

  • 3. Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?
    Pascale A, Serfaty L.
    J Hepatol; 2013 Feb; 58(2):391-4. PubMed ID: 23063419
    [Abstract] [Full Text] [Related]

  • 4. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G, Montano D, Abu Freha N, Etzion O, Dizingof V, Mushkalo A, Shwarts D, Monitin S, Takchick A, Zilberman D, Sikuler E, Fich A.
    Harefuah; 2016 May; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [Abstract] [Full Text] [Related]

  • 5. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.
    Antivir Ther; 2011 May; 16(5):695-704. PubMed ID: 21817191
    [Abstract] [Full Text] [Related]

  • 6. Faldaprevir, pegylated interferon, and ribavirin for treatment-naïve HCV genotype-1: pooled analysis of two phase 3 trials.
    Jensen DM, Asselah T, Dieterich D, Foster GR, Sulkowski MS, Zeuzem S, Mantry P, Yoshida EM, Moreno C, Ouzan D, Wright M, Morano LE, Buynak R, Bourlière M, Hassanein T, Nishiguchi S, Kao JH, Omata M, Paik SW, Wong DK, Tam E, Kaita K, Feinman SV, Stern JO, Scherer J, Quinson AM, Voss F, Gallivan JP, Böcher WO, Ferenci P.
    Ann Hepatol; 2016 May; 15(3):333-49. PubMed ID: 27049487
    [Abstract] [Full Text] [Related]

  • 7. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
    Calleja JL, Pascasio JM, Ruiz-Antorán B, Gea F, Bárcena R, Larrubia JR, Pérez-Álvarez R, Sousa JM, Romero-Gómez M, Solá R, de la Revilla J, Crespo J, Navarro JM, Arenas JI, Delgado M, Fernández-Rodríguez CM, Planas R, Buti M, Forns X, Spanish Group for the Study of the Use of Direct-Acting Drugs Hepatitis C with Severe Fibrosis.
    Liver Int; 2015 Jan; 35(1):90-100. PubMed ID: 25113158
    [Abstract] [Full Text] [Related]

  • 8. A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.
    Burton JR, O'Leary JG, Verna EC, Saxena V, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS, Terrault NA.
    J Hepatol; 2014 Sep; 61(3):508-14. PubMed ID: 24801415
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
    Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP, CUPIC Study Group.
    Gastroenterology; 2014 Jul; 147(1):132-142.e4. PubMed ID: 24704719
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
    Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.
    Gastroenterology; 2014 Jun; 146(7):1669-79.e3. PubMed ID: 24602923
    [Abstract] [Full Text] [Related]

  • 15. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?
    Coilly A, Dumortier J, Botta-Fridlund D, Latournerie M, Leroy V, Pageaux GP, Agostini H, Giostra E, Moreno C, Roche B, Antonini TM, Guillaud O, Lebray P, Radenne S, Saouli AC, Calmus Y, Alric L, Debette-Gratien M, De Ledinghen V, Durand F, Duvoux C, Samuel D, Duclos-Vallée JC.
    PLoS One; 2015 Jun; 10(9):e0138091. PubMed ID: 26394142
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors.
    Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF.
    PLoS One; 2014 Jun; 9(4):e94542. PubMed ID: 24728219
    [Abstract] [Full Text] [Related]

  • 19. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.
    Nelson DR.
    Liver Int; 2011 Jan; 31 Suppl 1():53-7. PubMed ID: 21205138
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.